Epigenetic modifications as therapeutic targets

Nature Biotechnology

Volumn 28, Issue 10, 2010, Pages 1069-1078

  Kelly, Theresa K ^a   De Carvalho, Daniel D ^a   Jones, Peter A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL USE; CYTOTOXIC; DEACETYLATION; DIAGNOSTIC INDICATORS; DISEASE PROGRESSION; DISEASE RISKS; DNA METHYLATION; EPIGENETIC MODIFICATION; GENETIC MECHANISM; HEMATOLOGICAL MALIGNANCIES; HISTONE METHYLATION; MALIGNANT TISSUES; MICRORNA EXPRESSION; NORMAL TISSUE; PROGNOSTIC INDICATORS; SIDE EFFECT; THERAPEUTIC INTERVENTION; THERAPEUTIC TARGETS; TRANSCRIPTIONAL ACTIVITY; US FOOD AND DRUG ADMINISTRATION;

ACETYLATION; ALKYLATION; METHYLATION; SIGNAL TRANSDUCTION;

PROTEINS;

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AZACITIDINE; BELINOSTAT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYTOCHROME P450; DEXAMETHASONE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DOXORUBICIN; FLUOROURACIL; HISTONE; ISTODAX; MICRORNA; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PACLITAXEL; PANOBINOSTAT; PCI 242781; PCI 24781; PXD 10; ROMIDEPSIN; S 110; SNDX 275; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR PITX2; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; NUCLEOSIDE;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ASTHMA; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DIABETES MELLITUS; DISEASE COURSE; DNA METHYLATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC POLYMORPHISM; GENOMIC INSTABILITY; HODGKIN DISEASE; HUMAN; HUNTINGTON CHOREA; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; METHYLATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; RETT SYNDROME; REVIEW; SARCOMA; SOLID TUMOR; SOTOS SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; DRUG EFFECTS; GENETIC EPIGENESIS; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; NEOPLASMS; NUCLEOSIDES;

EID: 77957937450     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1678     Document Type: Review

References (119)

1. Portela, A. & Esteller, M. Epigenetic modifcations and human disease. Nat. Biotechnol. 28, 1057-1068 (2010).
2. Meissner, A. Epigenetic modifcations and their role in pluripotency. Nat. Biotechnol. 28, 1079-1088 (2010).
3. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322 (2009).
4. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935 (2009).
5. Wu, S.C. & Zhang, Y. Active DNA demethylation: many roads lead to Rome. Nat. Rev. Mol. Cell Biol. 11, 607-620 (2010).
6. Jones, P.A. & Baylin, S.B. The epigenomics of cancer. Cell 128, 683-692 (2007).
7. Fouse, S.D. & Costello, J.F. Epigenetics of neurological cancers. Future Oncol. 5, 1615-1629 (2009).
8. Villeneuve, L.M. & Natarajan, R. The role of epigenetics in the pathology of diabetic complications. Am. J. Physiol. Renal Physiol. 299, F14-F25 (2010).
9. Javierre, B.M. et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 20, 170-179 (2010).
10. Adcock, I.M., Ito, K. & Barnes, P.J. Histone deacetylation: an important mechanism in infammatory lung diseases. COPD 2, 445-455 (2005).
11. Egger, G., Liang, G., Aparicio, A. & Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004).
12. Urdinguio, R.G., Sanchez-Mut, J.V. & Esteller, M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol. 8, 1056-1072 (2009).
13. Feng, J. & Fan, G. The role of DNA methylation in the central nervous system and neuropsychiatric disorders. Int. Rev. Neurobiol. 89, 67-84 (2009).
14. Sharma, S., Kelly, T.K. & Jones, P.A. Epigenetics in cancer. Carcinogenesis 31, 27-36 (2010).
15. Widschwendter, M. et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157-158 (2007).
16. Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232-236 (2007).
17. Ohm, J.E. et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39, 237-242 (2007).
18. Shen, L. et al. Integrated genetic and epigenetic analysis identifes three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 104, 18654-18659 (2007).
19. Seligson, D.B. et al. Global histone modifcation patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266 (2005).
20. Figueroa, M.E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13-27 (2010).
21. Ellinger, J. et al. Global levels of histone modifcations predict prostate cancer recurrence. Prostate 70, 61-69 (2010).
22. Bachmann, I.M. et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268-273 (2006).
23. Weller, M. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6, 39-51 (2010).
24. Kanai, Y. Genome-wide DNA methylation profles in precancerous conditions and cancers. Cancer Sci. 101, 36-45 (2010).
25. Kondo, T. et al. Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int. J. Oncol. 35, 547-557 (2009).
26. Shen, L. et al. Drug sensitivity prediction by CpG island methylation profle in the NCI-60 cancer cell line panel. Cancer Res. 67, 11335-11343 (2007).
27. Ibanez de Caceres, I. et al. IGFBP-3 hypermethylation-derived defciency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29, 1681-1690 (2010).
28. Voso, M.T. et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine effcacy in higher risk myelodysplastic syndromes. Clin. Cancer Res. 15, 5002-5007 (2009).
29. Martens, J.W., Margossian, A.L., Schmitt, M., Foekens, J. & Harbeck, N. DNA methylation as a biomarker in breast cancer. Future Oncol. 5, 1245-1256 (2009).
30. Jarmalaite, S. et al. Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study. J. Cancer Res. Clin. Oncol. 136, 847-854 (2010).
31. Baylin, S.B. & Ohm, J.E. Epigenetic gene silencing in cancer\-a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107-116 (2006).
32. Comoglio, P.M., Giordano, S. & Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516 (2008).
33. Cheng, J.C. et al. Preferential response of cancer cells to zebularine. Cancer Cell 6, 151-158 (2004).
34. Irizarry, R.A. et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specifc CpG island shores. Nat. Genet. 41, 178-186 (2009).
35. Issa, J.P. & Kantarjian, H.M. Targeting DNA methylation. Clin. Cancer Res. 15, 3938-3946 (2009).
36. Fenaux, P. et al. Effcacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10, 223-232 (2009).
37. Yoo, C.B., Cheng, J.C. & Jones, P.A. Zebularine: a new drug for epigenetic therapy. Biochem. Soc. Trans. 32, 910-912 (2004).
38. Yoo, C.B. et al. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67, 6400-6408 (2007).
39. Toyota, M., Ohe-Toyota, M., Ahuja, N. & Issa, J.P. Distinct genetic profles in colorectal tumors with or without the CpG island methylator phenotype. Proc. Natl. Acad. Sci. USA 97, 710-715 (2000).
40. Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 96, 8681-8686 (1999). (Pubitemid 29354851)
41. Tanemura, A. et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 15, 1801-1807 (2009).
42. Noushmehr, H. et al. Identifcation of a CpG island methylator phenotype that defnes a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
43. Van Rijnsoever, M., Elsaleh, H., Joseph, D., McCaul, K. & Iacopetta, B. CpG island methylator phenotype is an independent predictor of survival beneft from 5-fuorouracil in stage III colorectal cancer. Clin. Cancer Res. 9, 2898-2903 (2003).
44. Soengas, M.S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001).
45. Strathdee, G., MacKean, M.J., Illand, M. & Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335-2341 (1999).
46. Ma, X., Ezzeldin, H.H. & Diasio, R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69, 1911-1934 (2009).
47. Fukushima, T., Takeshima, H. & Kataoka, H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 29, 4845-4854 (2009).
48. Wargo, J.A. et al. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58, 383-394 (2009).
49. Wolff, E.M. et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 6, e1000917 (2010).
50. Feng, J. & Fan, G. The role of DNA methylation in the central nervous system and neuropsychiatric disorders. Int. Rev. Neurobiol. 89, 67-84 (2009).
51. Shi, Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat. Rev. Genet. 8, 829-833 (2007).
52. Yoo, C.B. & Jones, P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5, 37-50 (2006).
53. Nakagawa, M. et al. Expression profle of class I histone deacetylases in human cancer tissues. Oncol. Rep. 18, 769-774 (2007).
54. Lane, A.A. & Chabner, B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27, 5459-5468 (2009).
55. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009).
56. Haggarty, S.J., Koeller, K.M., Wong, J.C., Grozinger, C.M. & Schreiber, S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100, 4389-4394 (2003).
57. Balasub ramanian, S. et al. A novel histone deacetylase 8 (HDAC8)-specifc inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026-1034 (2008).
58. Bruserud, Ø., Stapnes, C., Ersvaer, E., Gjertsen, B.T. & Ryningen, A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 8, 388-400 (2007).
59. Fischer, A. et al. Recovery of learning and memory is associated with chromatin remodeling. Nature 447, 178-182 (2007).
60. Guan, J.S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55-60 (2007).
61. Ptak, C. & Petronis, A. Epigenetics and complex disease: from etiology to new therapeutics. Annu. Rev. Pharmacol. Toxicol. 48, 257-276 (2008).
62. Siu, L.L. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 26, 1940-1947 (2008).
63. Garcia-Manero, G. et al. Phase 1 study of the oral isotype specifc histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112, 981-989 (2008).
64. Lall, S. Primers on chromatin. Nat. Struct. Mol. Biol. 14, 1110-1115 (2007).
65. Huang, J. & Berger, S.L. The emerging feld of dynamic lysine methylation of non-histone proteins. Curr. Opin. Genet. Dev. 18, 152-158 (2008).
66. Lee, Y.H. & Stallcup, M.R. Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol. Endocrinol. 23, 425-433 (2009).
67. Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436-439 (2005).
68. Huang, Y. et al. Novel oligoamine analogues inhibit lysine-specifc demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 15, 7217-7228 (2009).
69. Schulte, J.H. et al. Lysine-specifc demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 69, 2065-2071 (2009).
70. Wang, J. et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41, 125-129 (2009).
71. Gal-Yam, E.N. et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl. Acad. Sci. USA 105, 12979-12984 (2008).
72. Mohammad, H.P. et al. Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specifc DNA hypermethylation. Cancer Res. 69, 6322-6330 (2009).
73. Tan, J. et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063 (2007).
74. Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699 (2008).
75. Miranda, T.B. et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588 (2009).
76. Cha, T.L. et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306-310 (2005).
77. Yu, J. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454 (2010).
78. Huang, J. et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J. Biol. Chem. 285, 9636-9641 (2010).
79. Kondo, Y. et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS ONE 3, e2037 (2008).
80. Kubicek, S. et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473-481 (2007).
81. Chang, Y. et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 16, 312-317 (2009).
82. Marango, J. et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111, 3145-3154 (2008).
83. Kim, H. et al. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J. Biol. Chem. 284, 19867-19877 (2009).
84. Cloos, P.A. et al. The putative oncogene GASC1 demethylates tri-and dimethylated lysine 9 on histone H3. Nature 442, 307-311 (2006).
85. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10, 704-714 (2009).
86. Eacker, S.M., Dawson, T.M. & Dawson, V.L. Understanding microRNAs in neurodegeneration. Nat. Rev. Neurosci. 10, 837-841 (2009).
87. Friedman, J.M. et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69, 2623-2629 (2009).
88. Ng, E.K. et al. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br. J. Cancer 101, 699-706 (2009).
89. Fabbri, M. et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 104, 15805-15810 (2007).
90. Saito, Y. et al. Specifc activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435-443 (2006).
91. Lujambio, A. et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA 105, 13556-13561 (2008).
92. Kota, J. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017 (2009).
93. McCaffrey, A.P. et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol. Ther. 16, 931-941 (2008).
94. Lanford, R.E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
95. Yanaihara, N. et al. Unique microRNA molecular profles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198 (2006).
96. Calin, G.A. & Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866 (2006).
97. Jahangeer, S., Elliott, R.M. & Henneberry, R.C. beta-Adrenergic receptor induction in HeLa cells: synergistic effect of 5-azacytidine and butyrate. Biochem. Biophys. Res. Commun. 108, 1434-1440 (1982).
98. Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G. & Baylin, S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21, 103-107 (1999).
99. Kuendgen, A. & Lubbert, M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann. Hematol. 87, 601-611 (2008).
100. Chen, J., Odenike, O. & Rowley, J.D. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer 10, 23-36 (2010).
101. Fandy, T.E. et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114, 2764-2773 (2009).
102. Soriano, A.O. et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110, 2302-2308 (2007).
103. Fiskus, W. et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114, 2733-2743 (2009).
104. Crea, F. et al. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol. Cancer Ther. 8, 1964-1973 (2009).
105. Ramalingam, S.S. et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 13, 3605-3610 (2007).
106. Ramalingam, S.S. et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for frst-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 56-62 (2010).
107. Satterlee, J., Schübeler, D. & Ng, H. Tackling the epigenome: challenges and opportunities for collaborative efforts. Nat. Biotechnol. 28, 1039-1044 (2010).
108. Bernstein, B.E. et al. The NIH Roadmap epigenomics mapping consortium. Nat. Biotechnol. 28, 1045-1048 (2010).
109. Rasheed, W., Bishton, M., Johnstone, R.W. & Prince, H.M. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev. Anticancer Ther. 8, 413-432 (2008).
110. Braiteh, F. et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 14, 6296-6301 (2008).
111. Balch, C., Fang, F., Matei, D.E., Huang, T.H. & Nephew, K.P. Minireview: epigenetic changes in ovarian cancer. Endocrinology 150, 4003-4011 (2009).
112. Lin, J. et al. A phase I dose-fnding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin. Cancer Res. 15, 6241-6249 (2009).
113. Berdasco, M. et al. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc. Natl. Acad. Sci. USA 106, 21830-21835 (2009).
114. Silverman, L.R. et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 24, 3895-3903 (2006).
115. Kantarjian, H.M. et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109, 265-273 (2007).
116. Gore, S.D. et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 7, 2330-2339 (2001).
117. Garcia-Manero, G. et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111, 1060-1066 (2008).
118. Kelly, W.K. et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23, 3923-3931 (2005).
119. Munster, P.N. et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 101, 1044-1050 (2009).